This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Tepper, Stewart
| Item Type | Name |
|
Concept
|
Calcitonin Gene-Related Peptide
|
|
Concept
|
Receptors, Calcitonin Gene-Related Peptide
|
|
Academic Article
|
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
|
|
Academic Article
|
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.
|
|
Academic Article
|
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
|
|
Academic Article
|
Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
|
|
Academic Article
|
Vascular safety of erenumab for migraine prevention.
|
|
Academic Article
|
Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.
|
|
Academic Article
|
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
|
|
Academic Article
|
Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine.
|
|
Academic Article
|
Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab.
|
|
Academic Article
|
New treatments for headache.
|
|
Academic Article
|
TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points.
|
|
Academic Article
|
Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
|
|
Academic Article
|
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.
|
|
Academic Article
|
Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
|
|
Academic Article
|
Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study.
|
|
Academic Article
|
Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
|
|
Academic Article
|
CGRP and headache: a brief review.
|
|
Academic Article
|
Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
|
|
Academic Article
|
Effects of acute and preventive therapies for episodic and chronic cluster headache: A scoping review of the literature.
|
|
Academic Article
|
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure.
|
|
Academic Article
|
Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine-Clinical Considerations: A Narrative Review.
|
|
Academic Article
|
Novel Migraine Treatments: A Review.
|
|
Academic Article
|
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
|
|
Academic Article
|
A Brief Review of Gepants.
|